Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Notes Payables (2017 - 2026)

Dr Reddys Laboratories has reported Notes Payables over the past 10 years, most recently at $646.9 million for Q1 2026.

  • For Q1 2026, Notes Payables rose 47.24% year-over-year to $646.9 million; the TTM value through Mar 2026 reached $646.9 million, up 47.24%, while the annual FY2026 figure was $646.9 million, 45.37% up from the prior year.
  • Notes Payables for Q1 2026 was $646.9 million at Dr Reddys Laboratories, up from $439.3 million in the prior quarter.
  • Over five years, Notes Payables peaked at $646.9 million in Q1 2026 and troughed at $89.9 million in Q1 2023.
  • A 5-year average of $337.9 million and a median of $360.2 million in 2022 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: tumbled 75.04% in 2023 and later skyrocketed 186.77% in 2025.
  • Year by year, Notes Payables stood at $360.2 million in 2022, then tumbled by 75.04% to $89.9 million in 2023, then soared by 70.42% to $153.2 million in 2024, then skyrocketed by 186.77% to $439.3 million in 2025, then surged by 47.24% to $646.9 million in 2026.
  • Business Quant data shows Notes Payables for RDY at $646.9 million in Q1 2026, $439.3 million in Q1 2025, and $153.2 million in Q1 2024.